SCHEMBL5347063

SCHEMBL5347063

CC(C)(C)OC(=O)N1CCC(CCOc2cccc(NC(=O)Nc3csc(Cl)n3)n2)CC1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.42
PKM P14618 1/20 0.42
CHEK2 O96017 1/20 0.41
GPR119 Q8TDV5 8/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
CCNA1 P78396 1/20 0.40
CDK5 Q00535 1/20 0.40
CDK5R1 Q15078 1/20 0.40
FAAH O00519 1/20 0.40
MAPT P10636 1/20 0.39
STS P08842 1/20 0.39
SCN9A Q15858 1/20 0.39
GLS O94925 1/20 0.39
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
CCNT1 O60563 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5346218 0.92 KDM4E (0.43) KDM4EPKMCHEK2GPR119CCNA2
SCHEMBL5343191 0.91 KDM4E (0.41) KDM4EPKMCHEK2GPR119FAAH
SCHEMBL5347747 0.89 GPR119 (0.42) KDM4EPKMCHEK2GPR119FAAH
SCHEMBL14558881 0.88 ACKR3 (0.48) KDM4EPKMCHEK2GPR119CCNA2
SCHEMBL5344526 0.87 CDK5 (0.49) KDM4EPKMCHEK2GPR119CDK5
SCHEMBL5342310 0.85 CDK5 (0.40) CCNA2CDK2CCNA1CDK5CDK5R1
SCHEMBL5354930 0.83 KDM4E (0.41) KDM4EPKMCHEK2GPR119MAPT
SCHEMBL5348983 0.82 CDK5 (0.40) CHEK2CCNA2CDK2CCNA1CDK5
SCHEMBL5345309 0.80 ACKR3 (0.49) KDM4EPKMGPR119CCNA2CDK2
SCHEMBL5341555 0.80 CDK5 (0.50) GPR119CDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
EP-1483263-A1 THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER Amgen Inc. (US) 2004-12-08 EP disclosed
US-20040044044-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2004-03-04 US disclosed
US-20040039029-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2004-02-26 US disclosed
US-6645990-B2 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases AMGEN INC. 2003-11-11 US disclosed
WO-2003070727-A1 THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2003-08-28 WO disclosed
US-20020193405-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2002-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193405-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX KDM4E 2714/4885PKM 580/4885CHEK2 82/4885
US-20040039029-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX KDM4E 2714/4885PKM 580/4885CHEK2 82/4885
US-20040044044-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX KDM4E 2714/4885PKM 580/4885CHEK2 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.